Pharmacodynamics of rFXIII
Dose, U/kg . | Increased activity, % . | Response, %/U/kg . |
|---|---|---|
| 20 | ||
| Patient 5 | 57 | 2.9 |
| Patient 6 | 59 | 3.0 |
| 50 | ||
| Patient 7 | 105 | 2.1 |
| Patient 8 | 122 | 2.4 |
| Patient 9 | 129 | 2.6 |
| 75 | ||
| Patient 10 | 181 | 2.4 |
| Patient 11 | 160 | 2.1 |
Dose, U/kg . | Increased activity, % . | Response, %/U/kg . |
|---|---|---|
| 20 | ||
| Patient 5 | 57 | 2.9 |
| Patient 6 | 59 | 3.0 |
| 50 | ||
| Patient 7 | 105 | 2.1 |
| Patient 8 | 122 | 2.4 |
| Patient 9 | 129 | 2.6 |
| 75 | ||
| Patient 10 | 181 | 2.4 |
| Patient 11 | 160 | 2.1 |
FXIII activity was measured and percentage increase in FXIII activity per unit per kilogram was calculated after a single dose of 20, 50, or 75 U/kg rFXIII. Patient 6 had normal levels of FXIII before dose, so data were baseline corrected before pharmacokinetic analyses. Patient 7 had FXIII B subunit deficiency.